insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

GTBP · Gt Biopharma, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · GTBP

1Y3YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$413.0K-$634.0K$363.0K$1.10M-$1.31M$1.78M$777.0K-
SG&A$2.44M-$2.75M$1.15M$833.0K-$2.30M$2.12M$2.31M-
Total Operating Expenses$488.0K---------
D&A----------
Operating Income($2.85M)-($3.38M)($1.51M)($1.93M)-($3.60M)($3.91M)($3.09M)-
Interest Expense$63.0K------$1.0K--
Income Tax----------
Net Income($2.83M)-($3.11M)($1.43M)($776.0K)-($3.41M)($3.71M)($2.27M)-
EPS - Basic($0.11)-($0.83)($0.55)($0.33)-($1.53)($2.17)($1.64)-
EPS - Diluted($0.11)-($0.83)($0.55)($0.33)-($1.53)($2.17)($1.64)-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$8.92M$6.81M$2.53M$5.23M$2.37M$3.95M$6.42M$9.25M$1.95M$1.08M
Accounts Receivable----------
Inventory----------
Accounts Payable$253.0K$748.0K$769.0K$1.37M$2.38M$3.85M$2.61M$1.72M$3.21M$4.33M
Current Assets$10.00M$8.11M$4.32M$7.12M$2.66M$4.23M$6.76M$9.27M$9.88M$14.06M
Total Assets-$8.11M$4.32M$7.12M-$4.23M$6.76M$9.27M$9.91M$14.11M
Current Liabilities$2.42M$2.32M$1.32M$2.31M$3.64M$5.90M$4.66M$3.76M$4.60M$6.63M
Long-term Debt----------
Total Liabilities--$1.32M$31.04M----$4.60M$6.63M
Stockholders' Equity$7.58M$5.79M$3.00M$2.86M($980.0K)($1.67M)$2.10M$5.51M$5.31M$7.48M
Retained Earnings($726.84M)($723.90M)($700.78M)($697.52M)($696.00M)($695.23M)($691.45M)($688.04M)($684.33M)($682.07M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($2.47M)---($2.20M)---($4.16M)-
Investing Cash Flow--------$5.03M-
Financing Cash Flow$4.58M---$616.0K-----
CapEx----------
Free Cash Flow----------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets---72.1%-20.1%---50.5%-40.0%-22.9%-
Return on equity-37.4%--103.8%-50.1%79.2%--162.7%-67.4%-42.7%-
Return on invested capital----------
Liquidity
Current ratio4.143.503.273.090.730.721.452.472.152.12
Quick ratio4.143.503.273.090.730.721.452.472.152.12
Cash ratio3.692.941.912.270.650.671.382.460.420.16
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage-45.2x-------3906.0x--
Equity multiplier-1.401.442.49--2.533.221.681.871.89
Liabilities / Assets--0.314.36----0.460.47
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B1.6x-0.8x3.5x--2.5x0.9x1.2x-
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)-47.4%-6.2%61.3%37.5%--15.4%-7.9%15.7%-
Net income growth (YoY)-265.1%-8.7%61.4%65.8%--41.2%-86.2%-898.2%-
EPS growth (YoY)66.7%-45.8%74.7%79.9%--2450.0%-2070.0%--
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)--43.1%-48.1%---79.0%-53.2%-59.3%-36.3%

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing GT Biopharma against the 5 most active filers in the same SIC group.